| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.50B | -4.3% |
| Gross profit | ¥0.17B | — |
| Operating income | ¥0.04B | — |
| Net income | ¥0.04B | -27.2% |
| Gross margin | 33.5% | Net margin 8.4% |
| Revenue Q/Q | -65.0% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.33B | 66.5% |
| R&D | ¥0.05B | 10.8% |
| SG&A | ¥0.10B | 19.0% |
| Tax & other | ¥0.00B | 0.1% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
建科院 ・ 华大基因 ・ 英科医疗 ・ 中科信息 ・ 电连技术 ・ 隆盛科技 ・ 英搏尔 ・ 朗新科技 ・ 海特生物 ・ 中石科技 ・ 艾德生物 ・ 智动力
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies